Holland Gary N, Vaudaux Jean D, Shiramizu Kevin M, Yu Fei, Goldenberg David T, Gupta Anurag, Carlson Margrit, Read Russell W, Novack Roger D, Kuppermann Baruch D
Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
Am J Ophthalmol. 2008 Jan;145(1):12-22. doi: 10.1016/j.ajo.2007.09.040.
To describe host characteristics (use of highly active antiretroviral therapy [HAART]; CD4+ T-lymphocyte count; HIV ribonucleic acid [RNA] blood level) of people who were diagnosed with AIDS-related cytomegalovirus (CMV) retinitis after HAART became available and to investigate effects of HAART on ophthalmic findings.
Retrospective, observational case series.
We collected demographic, medical, laboratory, and ophthalmic data for all patients with AIDS and newly diagnosed, untreated CMV retinitis from January 1997 through December 2000 at 10 sites in Los Angeles and Orange Counties, California.
The proportions of Hispanic and African-American patients were equivalent to or greater than their prevalences in the AIDS and general populations of Los Angeles County. Most patients (n = 80; 63.5%) were known to be receiving HAART at the time of CMV retinitis diagnosis; only 22 patients (17.5%) were HAART-naïve. Median CD4+ T-lymphocyte count was 15 cells/microl and median HIV RNA blood level was 103,000 copies/ml for all patients, but in 10 patients, CMV retinitis developed despite good immunologic and virologic responses to HAART. When compared with HAART-naïve patients, HAART-failure patients with CMV retinitis had more asymptomatic disease (P = .073), better visual acuity in the better eye (P = .003), more bilateral disease (P = .007), less zone 1 involvement (P = .042), and lower lesion border opacity scores (P = .054).
Most patients with AIDS and newly diagnosed CMV retinitis in an urban setting are HAART-experienced. HAART may influence characteristics of new CMV retinitis lesions at presentation, despite laboratory evidence of treatment failure, possibly because of residual CMV-specific immunity.
描述在高效抗逆转录病毒治疗(HAART)可用后被诊断为艾滋病相关巨细胞病毒(CMV)视网膜炎的患者的宿主特征(HAART的使用情况;CD4 + T淋巴细胞计数;HIV核糖核酸[RNA]血液水平),并研究HAART对眼科检查结果的影响。
回顾性观察病例系列。
我们收集了1997年1月至2000年12月期间在加利福尼亚州洛杉矶县和奥兰治县的10个地点,所有患有艾滋病且新诊断为未经治疗的CMV视网膜炎患者的人口统计学、医学、实验室和眼科数据。
西班牙裔和非裔美国患者的比例等于或高于他们在洛杉矶县艾滋病患者和普通人群中的患病率。大多数患者(n = 80;63.5%)在CMV视网膜炎诊断时已知正在接受HAART治疗;只有22名患者(17.5%)未接受过HAART治疗。所有患者的CD4 + T淋巴细胞计数中位数为15个/微升,HIV RNA血液水平中位数为103,000拷贝/毫升,但有10名患者尽管对HAART有良好的免疫和病毒学反应,仍发生了CMV视网膜炎。与未接受过HAART治疗的患者相比,发生CMV视网膜炎的HAART治疗失败患者无症状疾病更多(P = 0.073),较好眼的视力更好(P = 0.003),双侧疾病更多(P = 0.007),1区受累更少(P = 0.042),病变边界不透明度评分更低(P = 0.054)。
在城市环境中,大多数患有艾滋病且新诊断为CMV视网膜炎的患者都有HAART治疗经历。尽管有实验室证据表明治疗失败,但HAART可能会影响新出现的CMV视网膜炎病变的特征,这可能是由于残留的CMV特异性免疫力所致。